Gregg Kaiser, MD
Ophthalmology · Greenville, SCNPI 1386627925
Payments from drug & device makers
What this record shows
14 manufacturers reported payments, led by US Retina LLC at 50.8% of the total. Reporting peaked in 2022 at $1,233 and has fallen 57.9% since, to $520 in 2025.
Across 106 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Genentech USA, Inc.$545
- Regeneron Healthcare Solutions, Inc.$335
- Apellis Pharmaceuticals, Inc.$259
- Bausch & Lomb Americas Inc.$189
- Astellas Pharma US Inc$177
- plus $552 from 8 others
Across 4 payments — averaging $95,817 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$373K
- Regeneron$11K
What the payments were for
- Food & beverage$2,05749%
- Ownership interest$2,12151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $2,121 |
| Genentech USA, Inc. | 28 | $545 |
| Regeneron Healthcare Solutions, Inc. | 18 | $335 |
| Apellis Pharmaceuticals, Inc. | 9 | $259 |
| Bausch & Lomb Americas Inc. | 6 | $189 |
| Astellas Pharma US Inc | 8 | $177 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $138 |
| Novartis | 5 | $90 |
| AbbVie(2 entities) | 5 | $89 |
| Alimera Sciences, Inc. | 5 | $77 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $30 |
| Dutch Ophthalmic, USA | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,178 in reported general payments places this provider in the 65th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $7,443 |
| Prednisolone Acetate | 152 | $6,624 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,526 |
| ProlensaBromfenac Sodium | 11 | $3,862 |
| LumiganBimatoprost | 13 | $3,102 |
| Latanoprost | 166 | $1,225 |
| Timolol Maleate | 50 | $956 |
| Difluprednate | 17 | $916 |
| ValacyclovirValacyclovir Hcl | 12 | $748 |
| Ofloxacin | 64 | $690 |
| Brimonidine Tartrate | 26 | $566 |
| Ketorolac Tromethamine | 22 | $526 |
| ErythromycinErythromycin Base | 46 | $514 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $491 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $89 | $15,07137 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $138 | $3,86211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Greenville
- Alan LeaheyGreenville$35K
- William BallingerGreenville$14K
- Dilip ThomasGreenville$8K
- Brian WelcomeGreenville$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.